ABBV240705P185000
- 18.49
- 0.000.00%
AbbVie Newsroom
Sector Update: Health Care Stocks Steady Premarket Friday
Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) inactive. Bain Capital and Cinven are considering a potential jo
AbbVie Flags Hit to Q2 Adjusted Earnings From R&D Expenses, Revises 2024 Outlook
AbbVie (ABBV) expects its Q2 adjusted earnings to take a $0.52 per-share hit from acquired in-process research and development and milestones expense of $937 million on a pre-tax basis, according to a
AbbVie Q2 IPR&D Expenses to Lower EPS by $0.52
Express News | Abbvie Inc FY2024 Shr View $11.25 -- LSEG IBES Data
Express News | Abbvie -Q2 2024 Adjusted Diluted Earnings per Share Guidance Range, Including Impact of Q2 2024 Acquired Ipr&D, Milestones Expense $2.53 - $2.57
Express News | Abbvie: Earnings for Q2 of 2024 Expected to Include Acquired Ipr&D and Milestones Expense of $937 Mln on Pre-Tax Basis
Express News | Abbvie: 2024 Adj Diluted Eeps Guidance Range, Including Impact of Q2 2024 Acquired Ipr&D and Milestones Expense, Is $10.61 - $10.81
Express News | Cerevel Therapeutics Shares Are Trading Lower Amid Unconfirmed Rumors of a Recommendation Memo From FTC Staff to Challenge the AbbVie Merger
Watching Cerevel Therapeutics; Traders Circulating M&A Blog Comments Saying A Recommendation Memo From The Staff At The FTC To "Challenge" The CERE/ABBV Merger Is Being Considered
Watching Cerevel Therapeutics; Traders Circulating M&A Blog Comments Saying A Recommendation Memo From The Staff At The FTC To "Challenge" The CERE/ABBV Merger Is Being Considered
AbbVie Hits 4-week Low
Company News for Jul 3, 2024
A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts
7 analysts have expressed a variety of opinions on AbbVie (NYSE:ABBV) over the past quarter, offering a diverse set of opinions from bullish to bearish.Summarizing their recent assessments, the table
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 14.55% Piper Sandler $190 → $190 Maintains Overweight 06/20/2024 20.58% Cantor Fitzgerald $200
Express News | Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices
With 72% Ownership, AbbVie Inc. (NYSE:ABBV) Boasts of Strong Institutional Backing
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $190
Piper Sandler analyst Christopher Raymond maintains $AbbVie(ABBV.US)$ with a buy rating, and maintains the target price at $190.According to TipRanks data, the analyst has a success rate of 49.5% and
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
NORTH CHICAGO, Ill., July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a li
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $191
Morgan Stanley analyst Terence Flynn maintains $AbbVie(ABBV.US)$ with a buy rating, and maintains the target price at $191.According to TipRanks data, the analyst has a success rate of 65.0% and a tot
Buy Rating Affirmed for AbbVie on Strong Aesthetics Market Position and Positive Sales Outlook
AbbVie Names Robert A. Michael CEO; Richard A. Gonzalez To Become Executive Chairman
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael Joins AbbVie Board of DirectorsNORTH CHICAGO, Ill., July 1, 2024 /PRNewswi